Study reveals rising rates of depressive and anxiety disorders due to COVID-19 pandemic

Cases of major depressive disorder and anxiety disorders have increased by more than 25 per cent worldwide, according to a world-first study of the impact of COVID-19 on mental health.

The research, led by researchers from The University of Queensland's School of Public Health, Queensland Centre for Mental Health Research and Institute for Health Metrics and Evaluation (University of Washington) estimated people living in countries severely impacted by the COVID-19 pandemic have been most affected, especially women and younger people.

The study is the first to assess global impacts of the pandemic on major depressive and anxiety disorders, quantifying the prevalence and burden of the disorders by age, sex, and location in 204 countries and territories in 2020.

Study leader Dr Damian Santomauro said countries hit hardest by the pandemic in 2020 had the greatest rise in prevalence of the disorders.

We estimated that cases of major depressive disorder and anxiety disorders increased by 28 per cent and 26 per cent, respectively in 2020, with women affected more than men, and younger people affected more than older age groups.

Countries with high COVID-19 infection rates and major reductions in the movement of people – a consequence of measures such as lockdowns and school closures – were found to have the greatest increases in prevalence of major depressive disorder and anxiety disorders."

Dr Damian Santomauro, Study Leader

Other approaches to this research have generally focused on specific locations over a short window of time.

Dr Santomauro said mental health systems would need urgent strengthening to cope with the significant increase in cases of major depressive disorder and anxiety disorders, but taking no action should not be an option.

"Support services should be improved by promoting mental wellbeing, targeting factors contributing to poor mental health that have been made worse by the pandemic and improving treatment for those who develop a mental disorder," Dr Santomauro said.

"Even before the pandemic, mental health-care systems in most countries have historically been under-resourced and disorganized in their service delivery – so meeting the added demand for mental health services due to COVID-19 will be challenging."

Study co-author Dr Alize Ferrari said the study found that the COVID-19 pandemic had exacerbated many existing social inequalities that predispose people to developing mental disorders.

"Sadly, for numerous reasons, women are likely to be more affected by the social and economic consequences of the pandemic as they often carry the load when it comes to additional caring and household responsibilities," Dr Ferrari said.

"Women are also more likely to be victims of domestic violence, which has increased at various stages of the pandemic.

"School closures and wider restrictions limiting young people's ability to learn and interact with their peers, combined with the increased risk of unemployment, also meant young people were more heavily impacted by major depressive and anxiety disorders during the pandemic.

"It is crucial that policymakers take underlying factors such as these into account as part of measures to strengthen mental health services."

Source:
Journal reference:

COVID-19 Mental Disorders Collaborators (2021) Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet. doi.org/10.1016/S0140-6736(21)02143-7.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Psilocybin therapy reduces depression in clinicians after pandemic frontline work